Centene boosts guidance amid $1.1B Q2 profit, ACA membership drop
Elizabeth Casolo / beckershospitalreview - Centene brought in a $1.1 billion profit for the second quarter of 2026, up from a $253 million loss at the same time last year, according to the company’s July 28 earnings report. Total revenue approached $53.6 billion for the quarter, up nearly 10% year…
AI Summary: Centene reported a dramatic Q2 turnaround, posting about $1.1 billion in profit and raising its 2026 guidance despite an ACA membership decline. Executives credited improved margins and operational adjustments for the rebound, signaling a healthier financial posture as the company navigates policy and enrollment headwinds.
Prediction Market Betting on Drug Trials and Approvals Sparks Concern About Undermining Research
Rebecca Robbins / nytimes - Prediction markets on Kalshi and Polymarket now let people wager money on drug approvals. Kalshi also plans to allow bets on clinical trial results.
AI Summary: Betting platforms have started offering markets on clinical trial outcomes and FDA decisions, stirring alarms among regulators and researchers. Critics warn these markets could incentivize insider trading, leak-sensitive information, or distort trial conduct, prompting calls for oversight and clearer rules to protect scientific integrity and participant safety — because apparently Wall Street needed another hobby.